comparemela.com

Page 7 - Institut Gustave Roussy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mindpeak and Proscia Partner to Improve Cancer Diagnosis with Integrated AI-Powered Pathology Workflows

HAMBURG, Germany and PHILADELPHIA (PRWEB) June 20, 2023 Mindpeak, a leading provider of artificial intelligence (AI) for pathology,

United statesInstitut gustave roussyStephan frommeFelix faberNational pathology programmeInternational kiBreast cancer working groupStrategic alliancesDigital firstClinical transformation through pathologyInstitut gustave

Adding Talazoparib to Enzalutamide Appears Beneficial in mCRPC With HRR Mutations

Adding talazoparib to first-line treatment with enzalutamide improves rPFS in patients with HRR-deficient mCRPC, a phase 3 trial suggests.

France generalInstitut gustave roussyKarim fizaziAstellas pharma incPfizer incAstellas pharma

OSE Immunotherapeutics SA: OSE Immunotherapeutics Presents Clinical Abstracts on Tedopi at the ASCO 2023 Annual Meeting

Tedopi is the Company's Most Advanced Product in Clinical Development ATALANTE-1, a Phase 3 clinical trial with positive results comparing Tedopi to chemotherapy in non-small cell lung cancer

Mecklenburg vorpommernUnited statesFrance generalStefan klotterNicolas poirierFlorence portejoieSilvia comisInstitut gustave roussyGustave roussyBenjamin besseAlexandra learyBoehringer ingelheimWorld cancer research fund internationalAmerican society of clinical oncologyMerck co incSaclay university

OSE Immunotherapeutics Presents Clinical Abstracts on Tedopi® at the ASCO 2023 Annual Meeting

OSE Immunotherapeutics Presents Clinical Abstracts on Tedopi® at the ASCO 2023 Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalNicolas poirierGustave roussySilvia comisFlorence portejoieInstitut gustave roussyBenjamin besseAlexandra learyHead of clinical developmentWorld cancer research fund internationalMerck sharp dohme corpSaclay universityVeloxis pharmaceuticals incAmerican society of clinical oncologyBoehringer ingelheim

Adding Talazoparib to Enzalutamide Appears Beneficial in mCRPC With HRR Mutations

Adding talazoparib to first-line treatment with enzalutamide improves rPFS in patients with HRR-deficient mCRPC, a phase 3 trial suggests.

France generalKarim fizaziInstitut gustave roussyAstellas pharma incPfizer incAstellas pharma

vimarsana © 2020. All Rights Reserved.